Sachs -17th ELSF February 28-29 2024, Zurich, Switzerland
Vidac Pharma CEO Max Herzberg presented exciting new results of its VDA-1275 drug candidate at the Sachs 17 the Annual European Life Sciences CEO Forum in Zurich this week. The therapy showed strong synergistic effects in combination with two standard-of-care cancer treatments in organoid models of solid tumors. Vidac will publish results in a peer-reviewed article showing that VDA-1275 reduced the concentrations of sorafenib and cisplatin needed to reach IC50 by 50% and 95% respectively.
HTID 5 October 24-25.2023, Paris, France
Vidac Pharma was happy to participate in HTID#5 , where CEO Max Herzberg chaired an expert panel on non-violent therapies, particularly against cancer. The discussion made clear there is growing recognition by academics and the pharmaceutical community of the science behind Vidac's oncologic and onco-dermatologic drug candidates to treat diseases such as Actinic Keratosis, Cutaneous T-Cell Lymphoma and a wide range of solid tumors.
LinkedIn
Post HTID4 in Paris Update
We are honored to be one of the three innovation prize winners in the HTID4 in Paris, a remarkably organized conference. We are thankful for the organizers to have invited us to take part in this contest and give us the opportunity to make new business leads. We were also very impressed with the other companies in this conference.
Dr. Max Herzberg receiving a prize at HTID4 in Paris.
HTID4 in Paris
Vidac Pharma is proud to be part of the 25 innovative & disruptive companies, selected by European clusters, to pitch during HTID#4 in front of HealthTech For Care’s sponsors!
October 13&14, 2022
@HealthTech Place in Paris
Past Events